Good Distribution Practice: What the Guidelines Actually Require
A medicine can be manufactured perfectly and still reach the patient compromised. Good Distribution Practice governs everything that happens in between — and it is[…]
GMP Inspection Readiness: Annex 1 and the Contamination Control Strategy
The revised Annex 1 did more than tighten sterile manufacturing rules — it made the Contamination Control Strategy the organising document of your entire quality[…]
Variations and Lifecycle Management: What Changed for 2026
The EU variations framework has just been through its most significant revision in over a decade — and the rules changed on a different date[…]
eCTD Submissions: Avoiding the Most Common Deficiencies
An eCTD dossier can be scientifically flawless and still fail at the door. Most submission delays are technical, not clinical — and nearly all of[…]
Preparing for the EU HTA Regulation: A Practical Roadmap
The EU HTA Regulation is now live, and the Joint Clinical Assessment is reshaping how evidence is judged across Europe. The companies that prepare early[…]
Market Access for Biosimilars: Beyond the Price Tag
Biosimilars have saved European health systems tens of billions of euros — yet uptake remains uneven, and market access is about far more than offering[…]
Market Access for Rare Disease Therapies: Navigating Uncertainty
Rare disease therapies can transform lives — but getting them reimbursed is one of the hardest challenges in market access. Small populations, limited data and[…]
Signal Detection: Turning Safety Data into Action
Behind every label update and safety warning is a process that turns scattered adverse-event reports into a clear signal. Getting signal detection right is central[…]
The EU QPPV: Your Single Point of Accountability for Drug Safety
Every company marketing medicines in the EU must have one person permanently responsible for the safety of those products: the Qualified Person for Pharmacovigilance. It[…]
The EU Joint Clinical Assessment: What It Means for Your Product
From January 2025, the way new medicines are clinically assessed in Europe changed. The Joint Clinical Assessment (JCA) introduces a single, EU-wide evaluation of clinical[…]